The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Médico del ensayo/Coordinador del estudio
Dana Rizk
Correo electrónico Número de teléfono (205) 934-9509Nombre del sitio
The Kirklin Clinic of University Alabama Birmingham Hospital (Kirklin Clinic of UAB Hospital)
1720 2nd Avenue S, ZRB 614, Birmingham, AL 35294
The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Criterios de elegibilidad
Población de pacientes
Primary focal segmental glomerulosclerosis (FSGS)
Sobre el medicamento o la intervención
Qué implica para el paciente
Patients will participate for 13 weeks, receiving an intravenous infusion of the study drug weekly.
Nombre del patrocinador
Pfizer Inc.
Matrícula estimada
44
Fecha estimada de finalización
May, 2023
Sobre el estudio
Nombre del fármaco del estudio
PF-06730512
Objetivo del estudio
To evaluate the safety, tolerability, and possibily efficacy of PF-06730512 in patients with FSGS.
Sobre el medicamento o la intervención
PF-06730512 works as an antagonist, meaning it possibly reduces the biologic activity that is associated with FSGS.